The CRISPR gene-editing field has ignited a surge of investor enthusiasm from 2023 to 2025, drawing billions into companies pioneering therapies tailored to individual patients’ genetic profiles. This rush stems from CRISPR’s transformation from a basic research tool, discovered in 2012, into a cornerstone of personalized medicine, enabling precise DNA modifications to treat previously intractable diseases. As the market surges past $13 billion in 2025, fueled by regulatory wins and clinical breakthroughs, investors eye a future where one-time gene fixes could redefine healthcare economics.
Continue reading The Investor Gold Rush in Personalized CRISPR Medicine